May 2004 Table of Contents

External Link - article-94607.pdf

Articles in this issue

over 22 years ago

Article

The Risk Management Mandate

over 22 years ago

Article

Partners in Learning

over 22 years ago

Article

Early Warnings

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

What Life Sciences CEOs Are Losing Sleep Over in 2026

ByKen Banta

September 11th 2026

Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy

ByNicholas Jacobus

September 11th 2026

Leveraging Synthetic Advisory Boards for Sharper Biopharma Decisions

ByNacho Quinones, Ph.D.,Aisling O'Loughlin, Ph.D.

September 11th 2026

Novartis Investors Share Concerns Over M&A Strategy: Report

ByNicholas Jacobus

September 11th 2026

The Orchestra Needs a Conductor: Why Health Care Doesn’t Need More Point Solutions

ByMichelle Carnahan

September 11th 2026

May 2004 Table of Contents

Articles in this issue

Related Content

What Life Sciences CEOs Are Losing Sleep Over in 2026

Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy

Leveraging Synthetic Advisory Boards for Sharper Biopharma Decisions

Novartis Investors Share Concerns Over M&A Strategy: Report

The Orchestra Needs a Conductor: Why Health Care Doesn’t Need More Point Solutions

Trending on PharmExec

Novartis Investors Share Concerns Over M&A Strategy: Report

The Agentic AI Revolution in Biopharma

Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy

How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments

Artisan Partners’ Director Calls for Novartis Board Shake-Up